Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.
Continue ReadingUkko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.
Continue Reading9 Meters Biopharma, Inc., a clinical-stage company focused on rare and unmet needs in gastroenterology, announced their collaboration with the Celiac Disease Foundation to support clinical trial enrollment.
Continue ReadingThe Celiac Disease Foundation is proud to have been involved by recruiting patients essential for this trial’s success.
Continue ReadingThe NIH Accelerating Progress in Celiac Disease Workshop is a direct outcome of our advocacy efforts in Washington, DC. CEO Marilyn Geller was invited to speak about what our celiac community needs. Watch her presentation here.
Continue Reading
